▲ +147.28% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $16.44, with a high forecast of $27.00 and a low forecast of $12.00. The average price target represents a 147.28% upside from the last price of $6.65.
The current consensus among 10 contributing investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.